Last updated: February 13, 2026
Overview of NDC 00078-0345
NDC 00078-0345 refers to the drug Vimpat (lacosamide), indicated for partial-onset seizures in adults. It operates as a controlled substance (Schedule V), with a notable presence in epilepsy treatment. Lacosamide's market share has grown due to expanding indications and competitive pricing strategies.
Market Size and Growth Drivers
The global epilepsy treatment market was valued at approximately $7.89 billion in 2022, with a compound annual growth rate (CAGR) of around 4.3% projected through 2028 [1]. Vimpat’s market share depends on regional penetration, clinician adoption, and formulary preferences. The U.S. accounted for roughly 55% of the global epilepsy drug sales in 2022.
Drivers include:
- Increase in epilepsy prevalence—approximate rate of 1 in 26 Americans will develop epilepsy [2].
- Expansion of indication scope and approval for adjunctive treatments.
- Rising awareness and insurance coverage improvements.
Competitive Landscape
Key competitors:
| Drug Name |
Class |
Price (per 60 mg tablet) |
Market Share (2022) |
| Vimpat |
Lacosamide |
$115 - $130 |
18% |
| Keppra (levetiracetam) |
Broad-spectrum AED |
$20 - $30 |
22% |
| Tegretol (carbamazepine) |
Traditional |
$15 - $28 |
12% |
| Topamax (topiramate) |
Broad-spectrum AED |
$16 - $25 |
15% |
Vimpat’s pricing is higher than traditional generics but remains competitive with branded drugs delivering similar efficacy.
Price Trends and Projections (2023-2028)
Pricing has remained relatively stable but is subject to adjustment due to:
- Patent expiration timelines.
- Market competition.
- Formulary negotiations, especially with PBMs.
Based on current trends, price projections are:
| Year |
Estimated Price (per 60 mg tablet) |
Commentary |
| 2023 |
$125 |
Stable, with no major patent expiries upcoming |
| 2024 |
$120 |
Slight decrease expected as generics expand |
| 2025 |
$115 |
Further price erosion as generics gain market share |
| 2026 |
$110 |
Introduction of biosimilar or alternative formulations |
| 2027 |
$105 |
Increased competition may compress prices |
| 2028 |
$100 |
Price compression likely persists |
Market Entry and Regulatory Considerations
Vimpat was approved by the FDA in 2009. Pending patent protections primarily cover formulation and delivery mechanisms, with some patents expiring around 2024–2026. This expiration opens pathways for generic entry, likely exerting downward pressure on price.
Regulatory and Policy Factors
- The FDA’s approval of generics and biosimilars influences competition.
- CMS policies incentivize formulary adjustments favoring cost-effective therapies.
- Pricing transparency mandates and drug importation debates could impact pricing dynamics.
Implications for Stakeholders
- Manufacturers must monitor patent expiry timelines and plan for generic competition.
- Payers seek to optimize formulary management to balance efficacy and cost.
- Investors should track patent litigations and regulatory approvals for new formulations.
Key Takeaways
- Vimpat (NDC 00078-0345) maintains a solid but gradually declining price trajectory due to rising generic competition.
- The overall epilepsy market is growing, offering opportunities but increasing competition.
- Price decreases are expected to accelerate post-patent expiry, circa mid-2020s.
- Strategic positioning requires monitoring patent protection, regulatory pathways, and formulary trends.
- With a market cap estimated at over $1 billion, Vimpat remains relevant amid cost-containment pressures.
Frequently Asked Questions
1. When will patent protections for Vimpat expire?
Major patents are expected to expire between 2024 and 2026, opening the market to generics.
2. How does the introduction of generics impact Vimpat’s pricing?
Generic entry typically leads to a 30-50% price reduction within 1-2 years.
3. What are the main competitors to Vimpat?
Keppra (levetiracetam) and Topamax (topiramate) are primary competitors with broader market shares and lower prices.
4. What regional factors influence the market?
The U.S. dominates the epilepsy drug market with 55% of sales. European markets show slower growth but significant penetration.
5. Are biosimilars affecting the epilepsy drugs market?
Biosimilars are more relevant to biologics. For Vimpat, traditional generics are the primary competitive force.
Citations
[1] Grand View Research. "Epilepsy Drugs Market Size, Share & Trends Analysis." 2022.
[2] CDC. "Epilepsy Facts." 2023.
